CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain control, today announced that the British Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Wholesale Dealer’s License to Javelin’s UK subsidiary, Javelin Pharmaceuticals UK Limited. This represents a key commercialization step in anticipation of the product launch for Dyloject™ (diclofenac sodium 75mg / 2mL). Dyloject is currently under review for Marketing Authorization Application (MAA) approval in the UK also by the MHRA. Upon approval of the MAA for Dyloject, the Wholesale Dealer’s License permits Javelin Pharmaceuticals UK Limited, to commence distribution by way of wholesale dealing within the EEA of Dyloject in approved territories. Javelin Pharmaceuticals UK Limited, recently established offices at Compass House Park, Chivers Way Histon, Cambridge, CB4 9AD, United Kingdom. The new facility is managed by Mr. Derek Gallacher, Javelin’s European Managing Director.
